A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

(A ketamine-derived drug called esketamine is approved for some people as part of treatment-resistant major depressive disorder in a certified clinical setting.) But doctors have developed a ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Ketamine molecules contain two parts: S-ketamine (esketamine), which is like the left hand, and R-ketamine, which is like the right hand, McClure said. “Standard ketamine is a mixture of the two ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...

Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with depression and suicidal thoughts- especially when anti-depressants and talk ...

However, they may cover the FDA-approved nasal spray, Spravato, which contains a derivative of ketamine called esketamine. This article examines Medicare coverage for ketamine infusion ...

Intraoperative esketamine infusion significantly reduced the incidence of postpartum depression (PPD) at 6 weeks post partum ...

Esketamine, a molecular relative of regular ketamine, was approved as a TRD treatment in 2019, but until now, it had to be taken alongside a second, traditional antidepressant. Now, the new FDA ...

IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...